1811510-56-1 Usage
General Description
PF-6260933 is a potent and selective inhibitor of fatty acid amide hydrolase (FAAH), an enzyme that degrades endocannabinoids in the body. The chemical structure of PF-6260933 enables it to effectively block the activity of FAAH, leading to increased levels of endocannabinoids such as anandamide and 2-arachidonoylglycerol. This can have potential therapeutic implications in various conditions such as pain, inflammation, and anxiety. Additionally, PF-6260933 has shown promise in preclinical studies for its potential in treating neurodegenerative disorders and other neurological conditions. Overall, PF-6260933 has attracted attention as a potential pharmaceutical agent for targeting the endocannabinoid system and may have applications in the treatment of various diseases and disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 1811510-56-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,1,1,5,1 and 0 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1811510-56:
(9*1)+(8*8)+(7*1)+(6*1)+(5*5)+(4*1)+(3*0)+(2*5)+(1*6)=131
131 % 10 = 1
So 1811510-56-1 is a valid CAS Registry Number.
1811510-56-1Relevant articles and documents
Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment
Ammirati, Mark,Bagley, Scott W.,Bhattacharya, Samit K.,Buckbinder, Leonard,Carlo, Anthony A.,Conrad, Rebecca,Cortes, Christian,Dow, Robert L.,Dowling, Matthew S.,El-Kattan, Ayman,Ford, Kristen,Guimar?es, Cristiano R. W.,Hepworth, David,Jiao, Wenhua,Laperle, Jennifer,Liu, Shenping,Londregan, Allyn,Loria, Paula M.,Mathiowetz, Alan M.,Munchhof, Michael,Orr, Suvi T. M.,Petersen, Donna N.,Price, David A.,Skoura, Athanasia,Smith, Aaron C.,Wang, Jian
, p. 1128 - 1133 (2015/11/24)
Recent studies in adipose tissue, pancreas, muscle, and macrophages suggest that MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic drugs. As part of the evaluation of MAP4K4 as a novel antidiabetic target, a tool compound,
